SCHEMBL8206400

SCHEMBL8206400

CCOC(=O)N1CCC(NC(=O)c2cccc(NCc3cccnc3)n2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.56
MAPK1 P28482 2/20 0.56
TSHR P16473 1/20 0.56
KDM4E B2RXH2 5/20 0.49
HSD17B10 Q99714 4/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
NOS2 P35228 1/20 0.48
CCNA2 P20248 1/20 0.46
CDK2 P24941 1/20 0.46
CDK5 Q00535 1/20 0.46
CDK5R1 Q15078 1/20 0.46
VNN1 O95497 1/20 0.46
HPGD P15428 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
LMNA P02545 3/20 0.44
GAA P10253 2/20 0.44
RAB9A P51151 1/20 0.43
ADORA2A P29274 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12853586 0.85 ALDH1A1 (0.51) ALDH1A1MAPK1TSHRKDM4EHSD17B10
SCHEMBL8206380 0.84 KDM4E (0.51) ALDH1A1MAPK1TSHRKDM4EHSD17B10
SCHEMBL8206477 0.81 KMT2A (0.51) ALDH1A1MAPK1KDM4EHSD17B10MEN1
SCHEMBL17012010 0.81 KDM4E (0.58) ALDH1A1MAPK1KDM4EHSD17B10MEN1
SCHEMBL8208762 0.80 KDM4E (0.57) ALDH1A1MAPK1KDM4EHSD17B10MEN1
SCHEMBL8201484 0.80 KDM4E (0.57) ALDH1A1MAPK1KDM4EHSD17B10MEN1
SCHEMBL8213332 0.79 KDM4E (0.53) ALDH1A1MAPK1TSHRKDM4EHSD17B10
SCHEMBL12853598 0.79 NOS2 (0.67) ALDH1A1MAPK1KDM4EHSD17B10MEN1
SCHEMBL8209187 0.78 KDM4E (0.51) ALDH1A1MAPK1KDM4EHSD17B10MEN1
SCHEMBL12855299 0.77 KDM4E (0.60) ALDH1A1MAPK1KDM4EHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2132178-B1 JNK INHIBITORS MERCK SHARP & DOHME (US) 2015-08-19 EP disclosed
US-8278337-B2 Substituted pyridines that are JNK inhibitors MERCK SHARP & DOHME (US) 2012-10-02 US disclosed
US-8278337-B2 Substituted pyridines that are JNK inhibitors MERCK SHARP & DOHME (US) 2012-10-02 US disclosed
US-20100179141-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-07-15 US disclosed
US-20100179141-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-07-15 US disclosed
WO-2008082487-A2 NOVEL JNK INHIBITORS SCHERING CORPORATION (US) 2008-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179141-A1 NOVEL JNK INHIBITORS MAPK1, MAPKAPK5, MAPK15 ALDH1A1 3650/4885MAPK1 1/4885TSHR 3506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.